

# Celicia M Serenata

## List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/1399313/publications.pdf>

Version: 2024-02-01

20  
papers

860  
citations

933264

10  
h-index

839398

18  
g-index

21  
all docs

21  
docs citations

21  
times ranked

1079  
citing authors

| #  | ARTICLE   | IF   | CITATIONS |
|----|---|------|-----------|
| 1  | Dolutegravir plus Two Different Prodrugs of Tenofovir to Treat HIV. <i>New England Journal of Medicine</i> , 2019, 381, 803-815.  | 13.9 | 447       |
| 2  | Dolutegravir with emtricitabine and tenofovir alafenamide or tenofovir disoproxil fumarate versus efavirenz, emtricitabine, and tenofovir disoproxil fumarate for initial treatment of HIV-1 infection (ADVANCE): week 96 results from a randomised, phase 3, non-inferiority trial. <i>Lancet HIV</i> , 2020, 7, e666-e676.                | 2.1  | 145       |
| 3  | Reduced efficacy of HIV-1 integrase inhibitors in patients with drug resistance mutations in reverse transcriptase. <i>Nature Communications</i> , 2020, 11, 5922.  | 5.8  | 55        |
| 4  | Implications of weight gain with newer anti-retrovirals: 10-year predictions of cardiovascular disease and diabetes. <i>Aids</i> , 2021, 35, 1657-1665.   | 1.0  | 40        |
| 5  | The potential role of long-acting injectable cabotegravir+rilpivirine in the treatment of HIV in sub-Saharan Africa: a modelling analysis. <i>The Lancet Global Health</i> , 2021, 9, e620-e627.  | 2.9  | 31        |
| 6  | Phase 3 trials of new antiretrovirals are not representative of the global HIV epidemic. <i>Journal of Virus Eradication</i> , 2020, 6, 70-73.  | 0.3  | 20        |
| 7  | Impact of long-acting therapies on the global HIV epidemic. <i>Aids</i> , 2021, 35, S137-S143.  | 1.0  | 16        |
| 8  | Inclusion of pregnant women in antiretroviral drug research: what is needed to move forwards?. <i>Journal of the International AIDS Society</i> , 2019, 22, e25372.   | 1.2  | 15        |
| 9  | Participants on Dolutegravir Resuppress Human Immunodeficiency Virus RNA After Virologic Failure: Updated Data from the ADVANCE Trial. <i>Clinical Infectious Diseases</i> , 2021, 73, e1008-e1010.   | 2.9  | 15        |
| 10 | Weight gain stopping/switch rules for antiretroviral clinical trials. <i>Aids</i> , 2021, 35, S183-S188.  | 1.0  | 15        |
| 11 | Low-dose ritonavir-boosted darunavir once daily versus ritonavir-boosted lopinavir for participants with less than 50 HIV RNA copies per mL (WRHI 052): a randomised, open-label, phase 3, non-inferiority trial. <i>Lancet HIV</i> , 2019, 6, e428-e437.   | 2.1  | 14        |
| 12 | The predicted risk of adverse pregnancy outcomes as a result of treatment-associated obesity in a hypothetical population receiving tenofovir alafenamide/emtricitabine/dolutegravir, tenofovir disoproxil fumarate/emtricitabine/dolutegravir or tenofovir disoproxil fumarate/emtricitabine/efavirenz. <i>Aids</i> , 2021, 35, S117-S125. | 1.0  | 12        |
| 13 | Unexpected interactions between dolutegravir and folate: randomized trial evidence from South Africa. <i>Aids</i> , 2021, 35, 205-211.  | 1.0  | 11        |
| 14 | Patterns of Immune Activation in HIV and Non HIV Subjects and Its Relation to Cardiovascular Disease Risk. <i>Frontiers in Immunology</i> , 2021, 12, 647805.   | 2.2  | 8         |
| 15 | Cost and cost-effectiveness of dolutegravir-based antiretroviral regimens: an economic evaluation of a clinical trial. <i>Aids</i> , 2021, 35, S173-S182.   | 1.0  | 5         |
| 16 | Time to rethink endpoints for new clinical trials of antiretrovirals? Long-term re-suppression of HIV RNA with integrase inhibitors. <i>Aids</i> , 2020, 34, 321-324.   | 1.0  | 4         |
| 17 | Phase 3 trials of new antiretrovirals are not representative of the global HIV epidemic. <i>Journal of Virus Eradication</i> , 2020, 6, 70-73.  | 0.3  | 4         |
| 18 | What we have learned from antiretroviral treatment optimization efforts over the last 5 years?. <i>Aids</i> , 2021, 35, S113-S115.  | 1.0  | 2         |

| #  | ARTICLE  | IF  | CITATIONS |
|----|--|-----|-----------|
| 19 | Tracking adverse drug reactions and medication errors in the Central Chronic Medicine Dispensing and Distribution (CCMDD) programme in South Africa. Southern African Journal of HIV Medicine, 2022, 23, . | 0.3 | 1         |
| 20 | High individual pain variability in people living with HIV: A graphical analysis. European Journal of Pain, 2021, 25, 160-170.   | 1.4 | 0         |